BEIJING--(BUSINESS WIRE)--Sep 3, 2025--
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/
Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice ® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and sublicenses.
“We are excited to collaborate again with Merck KGaA, Darmstadt, Germany to explore the potential of antibody-conjugated lipid-based delivery systems,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration highlights the versatility of our fully human antibody platforms and the broad applications of antibodies beyond traditional therapeutics. By combining our antibody discovery expertise with Merck KGaA, Darmstadt, Germany’s established capabilities in LNPs, we look forward to accelerating the development of next-generation nucleic acid delivery solutions.”
“This collaboration will strengthen Merck KGaA, Darmstadt, Germany's position in providing LNP-based drug delivery solutions,” said Dr. Kahina Lang, Executive Director, Head of Next Gen Drug Delivery at Merck KGaA, Darmstadt, Germany. “We will be able to further improve the targeting specificity with our innovative design of antibody-conjugated LNPs. Our customers will gain access to a more comprehensive portfolio of delivery service offerings."
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab ™ / RenLite ® / RenNano ® / RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
HAMIMA, Syria (AP) — A trickle of civilians left a contested area east of Aleppo on Thursday after a warning by the Syrian military to evacuate ahead of an anticipated government military offensive against Kurdish-led forces.
Government officials and some residents who managed to get out said the Kurdish-led Syrian Democratic Forces prevented people from leaving via the corridor designated by the military along the main road leading west from the town of Maskana through Deir Hafer to the town of Hamima.
The SDF denied the reports that they were blocking the evacuation.
In Hamima, ambulances and government officials were gathered beginning early in the morning waiting to receive the evacuees and take them to shelters, but few arrived.
Farhat Khorto, a member of the executive office of Aleppo Governorate who was waiting there, claimed that there were "nearly two hundred civilian cars and hundreds of people who wanted to leave” the Deir Hafer area but that they were prevented by the SDF. He said the SDF was warning residents they could face “sniping operations or booby-trapped explosives” along that route.
Some families said they got out of the evacuation zone by taking back roads or going part of the distance on foot.
“We tried to leave this morning, but the SDF prevented us. So we left on foot … we walked about seven to eight kilometers until we hit the main road, and there the civil defense took us and things were good then,” said Saleh al-Othman, who said he fled Deir Hafer with more than 50 relatives.
Yasser al-Hasno, also from Deir Hafer, said he and his family left via back roads because the main routes were closed and finally crossed a small river on foot to get out of the evacuation area.
Another Deir Hafer resident who crossed the river on foot, Ahmad al-Ali, said, “We only made it here by bribing people. They still have not allowed a single person to go through the main crossing."
Farhad Shami, a spokesman for the SDF, said the allegations that the group had prevented civilians from leaving were “baseless.” He suggested that government shelling was deterring residents from moving.
The SDF later issued a statement also denying that it had blocked civilians from fleeing. It said that “any displacement of civilians under threat of force by Damascus constitutes a war crime" and called on the international community to condemn it.
“Today, the people of Deir Hafer have demonstrated their unwavering commitment to their land and homes, and no party can deprive them of their right to remain there under military pressure,” it said.
The Syrian army’s announcement late Wednesday — which said civilians would be able to evacuate through the “humanitarian corridor” from 9 a.m. to 5 p.m. Thursday — appeared to signal plans for an offensive against the SDF in the area east of Aleppo. Already there have been limited exchanges of fire between the two sides.
Thursday evening, the military said it would extend the humanitarian corridor for another day.
The Syrian military called on the SDF and other armed groups to withdraw to the other side of the Euphrates River, to the east of the contested zone. The SDF controls large swaths of northeastern Syria east of the river.
The tensions in the Deir Hafer area come after several days of intense clashes last week in Aleppo city that ended with the evacuation of Kurdish fighters and government forces taking control of three contested neighborhoods.
The fighting broke out as negotiations have stalled between Damascus and the SDF over an agreement reached last March to integrate their forces and for the central government to take control of institutions including border crossings and oil fields in the northeast.
Some of the factions that make up the new Syrian army, which was formed after the fall of former President Bashar Assad in a rebel offensive in December 2024, were previously Turkey-backed insurgent groups that have a long history of clashing with Kurdish forces.
The SDF for years has been the main U.S. partner in Syria in fighting against the Islamic State group, but Turkey considers the SDF a terrorist organization because of its association with Kurdish separatist insurgents in Turkey.
Despite the long-running U.S. support for the SDF, the Trump administration has also developed close ties with the government of interim Syrian President Ahmad al-Sharaa and has so far avoided publicly taking sides in the clashes in Aleppo.
Ilham Ahmed, head of foreign relations for the SDF-affiliated Kurdish-led administration in northeast Syria, at a press conference Thursday said SDF officials were in contact with the United States and Turkey and had presented several initiatives for de-escalation. She said that claims by Damascus that the SDF had failed to implement the March agreement were false.
——
Associated Press journalist Hogir Al Abdo in Qamishli, Syria, contributed.
Members of the Syrian military police stand at a humanitarian crossing declared by the Syrian army in the village of Hamima, in the eastern Aleppo countryside, near the front line with the Kurdish-led Syrian Democratic Forces in Deir Hafer, Syria, Thursday, Jan. 15, 2026. (AP Photo/Ghaith Alsayed)
Members of the Syrian Civil Defense, stand next to their vehicles at a humanitarian crossing declared by the Syrian army in the village of Hamima, in the eastern Aleppo countryside, near the front line with the Kurdish-led Syrian Democratic Forces in Deir Hafer, Syria, Thursday, Jan. 15, 2026. (AP Photo/Ghaith Alsayed)
A displaced Syrian family rides in the back of a truck near a humanitarian crossing declared by the Syrian army next to a river in the village of Rasm Al-Abboud, in the eastern Aleppo countryside, near the front line with the Kurdish-led Syrian Democratic Forces in Deir Hafer, Syria, Thursday, Jan. 15, 2026. (AP Photo/Omar Albam)
Displaced Syrian children and women ride in the back of a truck near a humanitarian crossing declared by the Syrian army in the village of Hamima, in the eastern Aleppo countryside, near the front line with the Kurdish-led Syrian Democratic Forces in Deir Hafer, Syria, Thursday, Jan. 15, 2026. (AP Photo/Omar Albam)
Displaced Syrians at a river crossing near the village of Jarirat al Imam, in the eastern Aleppo countryside, near the front line with the Kurdish-led Syrian Democratic Forces in Deir Hafer, Syria, Thursday, Jan. 15, 2026. (AP Photo/Omar Albam)
